The device was not returned for analysis.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effect of stenosis is listed in the xience sierra everolimus eluting coronary stent systems instructions for use as a known patient effect of coronary stenting procedures.A conclusive cause for the reported patient effect, and the relationship to the product, if any, cannot be determined; however, the subsequent treatment appears to be related to the operational context of the procedure.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
It was reported that the patient presented with a hypoglycemic event and chest pains.The procedure was to treat a restenosis in an unspecified artery.The 3.5x18mm xience sierra stent was implanted on (b)(6) 2020, however, the patient went back to the hospital on (b)(6) 2023 due to the stent being blocked by scar tissue.It was confirmed that the patient was compliant with dual antiplatelet drug therapy (dapt) after the procedure.Angiography was performed to confirm restenosis.A balloon was used to open up the implanted stent.The patient was discharged.There was no adverse patient sequelae.There was no clinically significant delay in the procedure.No additional information was provided.
|